Itsallaguess wrote:Bouleversee wrote:
It may be and hopefully will be but don't forget that they have administered doses with a 3 week interval which we only did briefly till it was changed to 12 weeks.
I'm not sure if you've seen much news about your concerns above this week?
...
Israeli study: 75% protection from 1st Pfizer vaccine dose, so okay to delay 2nd (19th Feb) -
[i]Pfizer’s vaccine is 75 percent effective two to four weeks after a single shot, according to a “groundbreaking” new Israeli study that may guide policy internationally on one of the most burning vaccine questions.
This figure reflects symptomatic and asymptomatic illness. When the Sheba Medical Center team homed in on stats just for people who felt unwell, they found that a single dose has 85% effectiveness.
...
On Thursday, Sheba researchers released research which it says supports the UK’s approach. Unlike most of the Israeli data on vaccine effectiveness, which hasn’t yet been subject to peer review, this study has been peer-reviewed and published in the prestigious journal The Lancet.
...
From the writeup I don't see how the Israeli research supports the conclusion that the 12 week dosing interval for the Pfizer vaccine is validated because they only looked at efficacy up to 4 weeks after the first shot beyond which data presumably could not be collected because everyone in Israel would have had their second shot by then. Yes, it's great to see significant efficacy shortly after one shot being demonstrated but to complete the analysis of whether the UK's decision has longer term consequences shouldn't studies also be done on how that one-shot-efficacy holds up 6, 8 all the way up to maybe 12 weeks after the first shot and maybe a few weeks beyond that to allow a bit of extra time both for the booster shot to add its effect and/or for people to be a week or two late in getting their 12 week booster? Presumably only the UK is in a position to collect that data on any meaningful scale since it is the only place (that I am aware of) implementing such a long dosing interval.
The other longer term effect that ideally should I assume be studied at some point is how do the efficacy against time curves running out to a year or more after the first dose compare for people who, for the various vaccines, were vaccinated at the recommended (phase 3 tested) dosing intervals vs the UK 12 week dosing interval in order to determine how extending the dosing intervals effects the longer term efficacy characteristics of the various vaccines.
I'm not saying we're all doomed, I am still of the opinion that especially for the AZ vaccine the UK made the right decision and, given the dire situation we were in around Christmas and into January, I can see why the decision was made to do the same with the Pfizer vaccine despite there being no data on extended dosing regimens there so it was a bigger risk, but it does seem to me that there is an awful lot more data that needs to be collected and analysed before we can say with any certainty what the consequences, if any, will be of extending the dosing interval particularly of the Pfizer and Moderna vaccines.
- Julian